[Yibai Pharmaceuticalrouletteplayingcards: Aidi Injection was cancelled from the selection of Guangdong Alliance Qingkailing and other proprietary Chinese medicines] Securities Times e Company NewsrouletteplayingcardsYibai Pharmaceutical (600594) announced on the evening of May 17. Recently, Guangdong Province Drug Exchange Center issued an announcement to cancel the sale of the company's product Aidi Injection in Guangdongrouletteplayingcards.rouletteplayingcards..
[Yibai Pharmaceutical: Aidi Injection has been cancelled from the selection status of centralized procurement of Chinese patent medicines such as Qingkailing in Guangdong Alliance] Securities Times e Company News, Yibai Pharmaceutical (600594) announced on the evening of May 17 that recently, Guangdong Province Drug Trading Center issued an announcement to cancel the selection status of the company's product Aidi Injection in centralized procurement of Chinese patent medicines such as Qingkailing in Guangdong Alliance. The operating income of Aidi Injection in the Guangdong Alliance supply area in 2020, 2021, 2022 and 2023 is 157 million yuan, 135 million yuan, 99 million yuan and 108 million yuan respectively, accounting for 21.31%, 19.53%, 20.51%, and 22.79% respectively.